Skip to main content
. 2021 Jun 16;7(25):eabf7820. doi: 10.1126/sciadv.abf7820

Fig. 3. In vitro binding.

Fig. 3

(A) Expression of VCAM-1 on C1498-WT and C1498-VCAM cells (gray, isotype antibody; green, anti–VCAM-1). (B and C) Binding of WT-NP (B) or VLA-NP (C) to C1498-WT or C1498-VCAM cells; blocking was performed by preincubating cells with anti–VCAM-1 (n = 3, mean + SD). ****P < 0.0001, Student’s t test. (D) Expression of VCAM-1 on untreated or LPS-treated bEnd.3 cells (gray, isotype antibody; green, anti–VCAM-1). (E and F) Binding of WT-NP (E) or VLA-NP (F) to untreated or LPS-treated bEnd.3 cells; blocking was performed by preincubating cells with anti–VCAM-1 (n = 3, mean + SD). **P < 0.01, Student’s t test.